You are here

sacituzumab govitecan

FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

CP Wire

sacituzumab govitecan

triple negative breast cancer

Flag link:

Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today

Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today

Motley Fool

sacituzumab govitecan

Flag link:

6 Key Cancer Winners From ASCO Presentations

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St

mirevtuximab soravtansine

Vascular Biogenics

sacituzumab govitecan

Flag link:

Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments

Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments

Yahoo

esophageal cancer

colorectal cancer

sacituzumab govitecan

Flag link: